Therapeutic Solutions International Files Patent on Campbell Score™: The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers

Rhea-AI Summary

Therapeutics Solutions International (OTC: TSOI) has filed a patent for the Campbell Score™, a groundbreaking method for assessing suicide risk through immunological parameters in blood samples. With an alarming estimate of 1.5 million lives lost to suicide in 2020, the company aims to shift the stigma surrounding mental health by scientifically linking suicidal tendencies to immune health. Director Kalina O'Connor, driven by personal tragedy, states that current evaluation methods are unreliable. The company also explores the use of QuadraMune™ to reduce inflammatory responses related to suicidal ideations.

Positive

• Filing of a patent for the Campbell Score™, a novel tool for assessing suicide risk.
• The potential to revolutionize suicide evaluation through scientific methods rather than subjective questionnaires.
• Opportunity to investigate QuadraMune™ impact on suicidal ideations linked to inflammation.

Negative

• None.

OCEANSIDE, Calif., Aug. 21, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI), announced today filing a patent covering immunological means of quantifying risk of suicide.  One embodiment of the patent is the Campbell Score™, a proprietary means of predicting risk of suicide based on assessment of immunological parameters from the blood of the patient.

"Since the beginning of time, suicide has been treated as a stigma, with victims being called 'selfish' and 'choosing the easy way out.' I am proud of the team and scientific advisors of Therapeutic Solutions International who have initiated the process of using solid science to establish suicide as an immunological disease," said Kalina O'Connor, Director of the Campbell Neurosciences Division of the Company and co-inventor of the patent. "By activating immune cells outside of the body using neurological chemicals, we can put our fingers on the pulse of the brain-immune interaction, which appears to be one of the critical factors controlling risk of suicide."

Kalina O'Connor's mother Kathleen Campbell was a victim of suicide.  The name Campbell Score™ was chosen in her honor.

"It is estimated that a minimum of 1.5 million people will die from suicide in 2020.  Furthermore, this is the second biggest cause of death for young people in the USA.  At present the only means of evaluating suicidal tendencies are through questionnaires, which are often unreliable due to patient reluctance to share relevant information," said Famela Ramos, former Congressional Candidate, co-inventor on the patent and Director of Business Development. "Working with the Team assembled by Ms. O'Connor, including internationally renowned inventor Howard Leonhardt and psychologist Erin Ferma, positions the Company to initiate the paradigm shift needed to change the way we look at suicide."

"The potential of immune hyperactivation being related to suicidal risk has been known for decades.  In the beginning days of cancer immunotherapy, observations were made that hyperactivation of immunity led to suicidal thoughts," stated Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent.  "It is of great interest to the Company to explore using agents such as QuadraMune™ in patients with inflammation associated suicidal ideations given that QuadraMune™ reduces interleukin-6, which is one of the components of the Campbell Score™."

"We are extremely thankful for our advisors and collaborators, and especially to Ms. O'Connor whose labor of love for her late mother has stimulated such scientific progress," said Timothy Dixon, President and CEO of the Company and co-inventor. "Given that we are already running a COVID-19 prevention trial using QuadraMune™, it will be exciting to explore the use of QuadraMune™ for prevention of suicidal ideations and to document reduction of the Campbell Score™ in clinical trials.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com , and our public forum is https://board.therapeuticsolutionsint.com/ 

Therapeutic Solutions International, Inc.
ir@tsoimail.com

 

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-files-patent-on-campbell-score-the-first-quantitative-tool-for-assessment-of-suicidal-propensity-based-on-immunological-markers-301116310.html

SOURCE Therapeutic Solutions International, Inc.

FAQ

What is the Campbell Score™ announced by Therapeutics Solutions International (OTC: TSOI)?

The Campbell Score™ is a patented method for predicting suicide risk based on immunological parameters from a patient's blood.

How does the Campbell Score™ aim to change suicide assessment?

It aims to provide a more reliable and scientific assessment of suicidal tendencies, moving away from traditional questionnaires.

What potential treatments are associated with the Campbell Score™?

The company plans to explore the use of QuadraMune™ in reducing inflammation associated with suicidal ideations.

What is the significance of the patent filing on August 21, 2020, for TSOI?

The patent filing signifies a potential breakthrough in understanding and assessing suicide risk, which could lead to improved treatment strategies.

Why was the Campbell Score™ named after Kathleen Campbell?

The name honors Kathleen Campbell, who was a victim of suicide, emphasizing the personal connection of the team's efforts to this research.